Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial

Journal of Clinical Oncology

Volumn 19, Issue 15, 2001, Pages 3447-3455

  Bramhall, S R ^a   Rosemurgy, A ^a   Brown, P D ^a   Bowry, C ^a   Buckles, J A C ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; MARIMASTAT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035424135     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.15.3447     Document Type: Article

References (28)

1. Cancer statistics, 1995
2. Trends in pancreatic cancer mortality in Europe, 1955-1989
3. Incidence, treatment and survival in 13,560 patients with pancreatic cancer: An epidemiological study in the West Midlands
4. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
5. Phase II trial of gemcitabine in patients with adenocarcinoma of the pancreas
6. Phase II study of gemcitabine in patients with advanced pancreatic cancer
7. Chemotherapy prolongs survival in inoperable pancreatic carcinoma
8. Chemotherapy in pancreatic cancer: Results of a controlled, prospective randomised, multicentre trial
9. An investigational new drug treatment program for patients with gemcitabine
10. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
11. Regulation of matrix metalloproteinases: Their role in tumor invasion and metastasis
12. Matrix metalloproteinase inhibition: A review of anti-tumor activity
13. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma
14. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer
15. A matrix metalloproteinase expressed on tine surface of invasive tumour cells
16. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metanoproteinase inhibitor
17. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
18. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models
19. Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: Relationship with levels of circulating CEA
20. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumourogenesis in vivo
21. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer
22. A phase II study of marimastat in advanced pancreatic cancer
23. Cancer of the pancreas: 50 years of surgery
24. Pancreatic cancer: Nihilism is obsolete!
25. Adjuvant chemotherapy in pancreatic cancer
26. Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro
27. Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins